K

Alexandria Venture Investments logo

Alexandria Venture Investments

Crunchbase
Pitchbook
Crunchbase

Deals on record

24

Common Fundraising Type

Series B

Galatea Bio logo
Galatea Bio

AI-driven • Genomic research

Stanford logo
Helios Digital Ventures logo
HBM Genomics logo
Founders Collective logo

Galatea Bio is a biotechnology company that uses AI-driven genomic research and clinical genetic testing to advance precision medicine and improve genetic risk analysis, biomarker discovery, and clinical trials optimization.

Equity
$25M
03/27/2025
Article
Latigo Biotherapeutics logo
Latigo Biotherapeutics

Non-opioid • Pain treatments

Blue Owl Capital logo
Westlake Village BioPartners logo
UPMC Enterprises logo
Sanofi Ventures logo

Latigo Biotherapeutics develops non-opioid pain treatments, focusing on selective Nav1.8 inhibitors.

Series B
$150M
03/17/2025
Article
Eikon Therapeutics logo
Eikon Therapeutics

Biotechnology • Drug Discovery

Lux Capital logo
UC Investments logo
T. Rowe Price Associates logo
StepStone Group logo

Eikon Therapeutics develops new medicines using advanced technologies like single-molecule tracking and high-performance computing to accelerate drug discovery and development.

Series D
$350.7M
02/26/2025
Article
Umoja Biopharma logo
Umoja Biopharma

Biotechnology • In vivo cell therapies

University of Minnesota Endowment logo
SoftBank logo
RTW Investments logo
Qiming Venture Partners USA logo

Umoja Biopharma is a biotechnology company focused on developing in vivo CAR T cell therapies for oncology and autoimmune diseases using its VivoVec™ gene delivery technology.

Series C
$100M
01/20/2025
Article
nChroma Bio logo
nChroma Bio

Epigenetic editing • Genetic medicines

Wilson Sonsini Goodrich & Rosati logo
Wellington Management logo
T. Rowe Price logo
Sofinnova Partners logo

nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Equity
$75M
12/11/2024
Article
Nuvig Therapeutics logo
Nuvig Therapeutics

Biotechnology • Autoimmune Diseases

Sanofi Ventures logo
Blue Owl Healthcare Opportunities logo
Norwest Venture Partners logo
Novo Holdings logo

Nuvig Therapeutics is a biotechnology company developing treatments for autoimmune diseases that do not rely on immunosuppression.

Series B
$161M
12/05/2024
Article
Autoimmunity BioSolutions logo
Autoimmunity BioSolutions

Biotechnology • Immuno-corrective therapies

Independent Capital logo
Eos BioInnovation logo
Alexandria Venture Investments logo

Autoimmunity BioSolutions develops next-generation immuno-corrective therapies targeting genetically-defined subpopulations of patients with autoimmune diseases.

Seed
$2M
11/28/2024
Article
Valora Therapeutics logo
Valora Therapeutics

Biotechnology • Immunotherapeutics

Valora Therapeutics Inc. is a biotechnology company developing novel immunotherapeutics using its proprietary AbLec platform to modulate glyco-immune checkpoints.

Seed
$30M
11/20/2024
Article
TRexBio logo
TRexBio

Biotechnology • Inflammatory Diseases

Delos Capital logo
Avego BioScience Capital logo
SV Health Investors logo
Pfizer Ventures logo

TRexBio is a biotechnology company developing novel therapies for inflammatory diseases using their Deep Biology platform to focus on immune homeostasis.

Series B
$84M
11/13/2024
Article
Leal Therapeutics logo
Leal Therapeutics

Biotechnology • Central Nervous System

Chugai Venture Fund logo
Newpath Partners logo
PhiFund logo
OrbiMed logo

Leal Therapeutics is a biotechnology company developing treatments for central nervous system disorders, focusing on amyotrophic lateral sclerosis (ALS) and schizophrenia.

Equity
$45M
10/30/2024
Article
Archon Biosciences logo
Archon Biosciences

AI-driven • Computational protein design

WRF Capital logo
Sahsen Ventures logo
Pack Ventures logo
Madrona Ventures logo

Archon Biosciences develops AI-driven Antibody Cages to enhance antibody treatments by improving target engagement and biodistribution.

Seed
$20M
10/30/2024
Article
Axonis Therapeutics logo
Axonis Therapeutics

Biotechnology • Neuromedicines

venBio Partners logo
Sofinnova Investments logo
Solasta Ventures logo
SCI Ventures logo

Axonis Therapeutics is a biotechnology company developing novel neuromedicines targeting neurological disorders like epilepsy and pain.

Series A
$115M
10/30/2024
Article
Passkey Therapeutics logo
Passkey Therapeutics

Therapeutic development • Protein targeting

Innovation Endeavors logo
Wireframe Ventures logo
GRIDS Capital logo
Breakout Ventures logo

Passkey Therapeutics develops novel therapies that target rare protein combinations to treat complex diseases like cancer and autoimmune disorders.

Seed
$20M
10/22/2024
Article
Terray Therapeutics logo
Terray Therapeutics

Biotechnology • Small Molecule Drug Discovery

XTX Ventures logo
Two Sigma Ventures logo
NVentures logo
Maverick Capital logo

Terray Therapeutics integrates ultra-high throughput experimentation with generative AI, biology, medicinal chemistry, automation, and nanotechnology to transform small molecule drug discovery.

Series B
$120M
10/17/2024
Article
858 Therapeutics logo
858 Therapeutics

Biotechnology • Small molecule therapeutics

Avidity Partners logo
Versant Ventures logo
NEA logo
Mirae Asset Capital logo

858 Therapeutics is a biotechnology company developing small molecule therapeutics for oncology and immunology, with a lead asset, ETX-19477, in Phase 1 trials for advanced solid tumors.

Series B
$50M
09/26/2024
Article
Radiant Bio logo
Radiant Bio

Multabody™ platform • Oncology

Amplitude Ventures logo
Toronto Innovation Acceleration Partners logo
FACIT logo
Bill & Melinda Gates Foundation logo

Radiant Biotherapeutics develops innovative therapies using its proprietary Multabody™ platform to target oncology, inflammation, immunology, and infectious diseases.

Series A
$35M
09/11/2024
Article
Ability Biologics logo
Ability Biologics

Antibody Therapeutics • Preclinical Development

Amplitude Ventures logo
Fonds de solidarit FTQ logo
Page One Ventures logo
Charles River Laboratories logo

Ability Biologics is a biotech startup focused on creating next-generation antibody therapeutics for unmet medical needs using their proprietary AI platform, AbiLeap™.

Seed
$12M
12/06/2023
Article
Odyssey Therapeutics logo
Odyssey Therapeutics

Biotechnology • Immunomodulators

Woodline Partners logo
Walleye Capital logo
Leerink Partners logo
The Global BioAccess Fund logo

Odyssey Therapeutics is a biotech firm specializing in developing precision immunomodulators and oncology medicines, with plans to advance multiple therapeutic programs into clinical studies.

Series C
$101M
12/05/2023
Article
Seismic Therapeutic logo
Seismic Therapeutic

Biotechnology • Drug Discovery

Bessemer Venture Partners logo
Timothy A. Springer logo
Samsara BioCapital logo
Polaris Partners logo

Seismic Therapeutic is a biotechnology firm specializing in the development of immunology drugs using a machine learning-enabled platform to advance its biologics pipeline through clinical trials.

Series B
$121M
12/04/2023
Article
Alto Neuroscience logo
Alto Neuroscience

Precision Psychiatry • Brain Biomarkers

InVivium Capital logo
Windham Venture Partners logo
WhatIf Ventures logo
Point72 logo

Alto Neuroscience specializes in precision psychiatry, developing targeted medicines based on its Precision Psychiatry Platform™, which utilizes brain biomarkers to match patients with appropriate treatments.

Series C
$45M
11/21/2023
Article
Triveni Bio logo
Triveni Bio

Biotech • Antibody treatments

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Series A
$92M
10/26/2023
Article
Deka Biosciences logo
Deka Biosciences

Biotech • Immunotherapy

MPM BioImpact logo
Viva BioInnovator logo
Plains Ventures logo
Lumira Ventures logo

Deka Biosciences is a biotech company that aims to improve immunotherapy treatments by combining biology with precision medicine, specifically through their investigational new drug, DK210 (EGFR), which has dissociated IL-2 potency from toxicity.

Series B
$20M
09/28/2023
Article
Arialys Therapeutics logo
Arialys Therapeutics

Biotechnology • Neuropsychiatric Disorders

MPM BioImpact logo
Johnson & Johnson Innovation logo
Catalys Pacific logo
Avalon BioVentures logo

Arialys Therapeutics is a biotechnology company that develops precision medicines to target pathogenic autoantibodies in the central nervous system, with a focus on treating neuropsychiatric diseases caused by autoimmunity.

Seed
$58M
09/13/2023
Article
ROME Therapeutics logo
ROME Therapeutics

Biotechnology • Autoimmune Diseases

Section 32 logo
Sanofi Ventures logo
Raycap logo
Mirae Asset Capital logo

ROME Therapeutics is a biotechnology company that develops breakthrough medicines for serious diseases, with a focus on an inhibitor of LINE-1 reverse transcriptase for autoimmune diseases, using their proprietary data science platform to identify active repeat elements and assess their roles in disease.

Series B
$72M
09/12/2023
Article